Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) suffers a larger drop than the general market: Key insights
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.90, marking a -4.88% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.51% for ...
BUFFALO GROVE, ILLINOIS / ACCESS Newswire / February 4, 2026 / PPC Flex, a leader in high-performance sterile and ...
The FTC settled a lawsuit against Express Scripts over allegations that the company artificially inflated the price of ...
Michigan AG Nessel secured $17.85 million in settlements with Lannett and Bausch over drug price-fixing claims.
“The global API manufacturing market is going through some major changes these days,” says Sean O’Brien, COO, Abzena. He ...
FDA leaders tried to quell concerns about a controversial new program to fast-track certain drugs at an employee town hall ...
Danish obesity drug maker Novo Nordisk's new CEO risks being on the losing side of a damaging price war as "unprecedented" ...
Nanologica, a life sciences company that makes silica-based peptides for the pharmaceutical industry, acquired CDMO Ardena’s Syntagon manufacturing facility in a stock deal valued at 8.6 million ...
HANGZHOU CITY, ZHEJIANG, CHINA, January 19, 2026 /EINPresswire.com/ -- With the development of the pharmaceutical and ...
The pharmaceutical industry operates under an uncompromising mandate: zero defects. Every tablet, capsule, vial, or syringe must meet exacting standards for dosage, purity, and sterility. This ...
The legislation will impose new restrictions on pharmacy benefit managers, giant companies like CVS Caremark, Optum Rx and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results